Genmab — August 2020
-
The very important conference call on 26 August, Danish time 4.30 pm is announced here. Organizer and analysts are from the famous Genmab chat. https://ir.genmab.com/events-and-presentations#content
-
-
Questions are very welcome as soon as possible.
-
Fra DnB: Target price raised to DKK2,455 (2,450); HOLD reiterated. Following the approval of Kesimpta, we have lifted our probability of success to 100% (previously 95%), adding DKK5 to our target price. However, we believe this is well reflected in the stock price.
-
God morrgen.
-
Hvornår går Kesimpta af patent? Azerras patent udløber så vidt jeg finde oplysninger om i 2023. Da Ofa i Kesimpta er anderledes (sc) ligger udløb længere ude i fremtiden, men jeg kan ikke finde slutåret?
-
Daratumumab with Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma https://www.sciencedirect.com/science/article/pii/S2152265020304237
-
Immune-based therapies in the management of multiple myeloma https://www.nature.com/articles/s41408-020-00350-x
-
Tak Solsen. Vi kan bruge rigtig mange flere spørgsmål.
-
Ser ud til TA indikere mulig kurs op til 2550 inden næste retracement såfremt den positive nyhedsstrøm fortsætter kommende uger. https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/86145_target_2554.JPG
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind